<DOC>
	<DOC>NCT02732743</DOC>
	<brief_summary>The primary objective is to assess the efficacy and safety of the Food Supplement Physiomanna® Baby in pediatric patients with a history of functional constipation The secondary objective of the trial is to evaluate the adherence to product's administration in the enrolled children.</brief_summary>
	<brief_title>Food Supplement Physiomanna® Baby in Pediatric Patients</brief_title>
	<detailed_description>This is an interventional, non-controlled, multicenter trial with a prospective design in one cohort of patients. This clinical investigation will be performed in 3 centers in Romania. The tested hypothesis is that Physiomanna® Baby administration for 3 weeks, increases the SBM to be more than 2 times per week.</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Male or female outpatients between the ages of 0 to 8 years; Functional constipation according to ROME III criteria (Annex 2); Two or fewer SBM during the previous week; SBM is defined as BM not preceded after a 24 h administration with a laxative or enema; To be otherwise in good health, as judged by a physical examination; Mentally competent parent or tutor to sign an informed consent Known history of organic cause for the constipation; Congenital malformations that produce constipation (Hirschsprung's disease, imperforate anus, children with cerebral palsy or other neurologic abnormalities, or systemic diseases); Fecal Occult Blood Test (FOBT) positive in the 4 previous weeks; Fecal impaction at baseline, or during the trial period, as indicated by the physical examination; Known or suspected perforation or obstruction other than fecal impaction; History of gastric retention, inflammatory bowel disease, bowel resection, or colostomy; Use of concomitant medications that cause constipation in the previous 3 months; Concomitant use of herbs and other dietary supplements, such as: stimulant laxative herbs and/or potassium depleting herbs; Concomitant use of cardiac glycosides(e.g. Digoxin); Patients who, according to the investigator, should not be included in the study for any reason, including the parent's inability to follow the study procedures; Patients with known allergy to Fraxinus Manna, mannitole, fennel, lemon balm or chamomile; Patients with clinically significant elevations of TSH or abnormal plasma electrolytes in the 4 previous weeks; Patients who, within the past 30 days have participated in an investigational clinical study;</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>8 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>childhod constipation</keyword>
</DOC>